RecruitingPhase 3NCT06315322
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Studying Childhood absence epilepsy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UCB Biopharma SRL
- Intervention
- Brivaracetam Film-coated tablet(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2024 – 2030
Study locations (23)
- Ep0224 50140, Birmingham, Alabama, United States
- Ep0224 50639, Orange, California, United States
- Ep0224 50268, Miami, Florida, United States
- Ep0224 50638, New Brunswick, New Jersey, United States
- Ep0224 50640, Winston-Salem, North Carolina, United States
- Ep0224 20321, Tbilisi, Georgia
- Ep0224 20322, Tbilisi, Georgia
- Ep0224 20323, Tbilisi, Georgia
- Ep0224 20324, Tbilisi, Georgia
- Ep0224 40144, Abbiategrasso, Italy
- Ep0224 40765, Messina, Italy
- Ep0224 40764, Pavia, Italy
- Ep0224 40629, Roma, Italy
- Ep0224 40766, Roma, Italy
- Ep0224 40763, Verona, Italy
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06315322 on ClinicalTrials.govOther trials for Childhood absence epilepsy
Additional recruiting or active studies for the same condition.